Will Psychedelic Stocks Be The New ESG Favorites For 2021?

While many investors remain purely focused on profits, a new class of investor has been acquiring greater prominence in recent years: the “socially conscious investor”.

These investors focus not only on profit/loss parameters but also on how companies measure up in terms of Environmental, Social, and Governance criteria. Known as ESG investing, companies that make positive contributions to the environment or society are being rewarded for these good deeds – via more investor dollars.

Why psychedelic drug stocks are strong ESG candidates

Investors are becoming more educated about psychedelic drugs and psychedelic drug medicine. As they learn more, psychedelic stocks are looking more and more like not merely great investment opportunities, but great ESG investment opportunities.

Why?

Start with the obvious. We are in the midst of a rapidly-worsening Mental Health Crisis that already afflicts over 1 billion people – centering on stress-related conditions like depression, anxiety, addiction, and PTSD.

The COVID pandemic is causing rates of depression, anxiety, and addiction to skyrocket. Existing therapies for these conditions have proven grossly inadequate.

This is a humanitarian catastrophe. Want to do something about it?

Invest in psychedelic drug stocks.

Clinical research on these psychedelic substances is showing the clear potential to revolutionize mental health care. Instead of ineffectually treating symptoms (the current standard of care), psychedelic medicine represents potential cures for these conditions. See: Psychedelic Drugs: Powerful Medicines, Life-Changing Results

Behind only hunger, poverty, and war, the Mental Health Crisis is the greatest humanitarian crisis on the planet today.

You won’t find an investment that can “cure” hunger, poverty, or war. But you can invest in cures for the Mental Health Crisis.

Also, looking to make investments that support the economy? Psychedelic drug stocks.

1 2 3
View single page >> |

Disclosure: The writer holds shares in MindMed Inc, Numinus Wellness, Cybin Corp and Mind Cure Health. Mind Cure Health is a client of Psychedelic Stock Watch.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.